参考文献/References:
[1] Li P,Ge J,Li H. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease[J]. Nat Rev Cardiol,2020,17(2):96-115.
[2] Man K,Brunet M,Fernandez-Rhodes M,et al. Epigenetic reprogramming enhances the therapeutic efficacy of osteoblast-derived extracellular vesicles to promote human bone marrow stem cell osteogenic differentiation[J]. J Extracell Vesicles,2021,10(9): e12118.
[3] Bai L,Kee H,Choi S,et al. HDAC5 inhibition reduces angiotensin Ⅱ-induced vascular contraction,hypertrophy,and oxidative stress in a mouse model[J].Biomed Pharmacother,2021,134:111162.
[4] Chi Z,Byeon H,Seo E,et al. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation[J]. Pharmacol Res,2019,146:104281.
[5] Choi J,Park S,Kwon T,et al. Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin Ⅱ axis[J].Int J Obes (Lond),2017,41(11):1702-1709.
[6] Guo J,Wang Z,Wu J,et al. Endothelial SIRT6 is vital to prevent hypertension and associated cardiorenal injury through targeting Nkx3.2-GATA5 signaling[J].Circ Res,2019,124(10):1448-1461.
[7] Asare Y,Campbell-James T,Bokov Y,et al. Histone deacetylase 9 activates IKK to regulate atherosclerotic plaque vulnerability[J].Circ Res,2020,127(6):811-823.
[8] Toulassi I,Al Saedi U,Gutlapalli S,et al. A paradigm shift in the management of atherosclerosis:protective role of sirtuins in atherosclerosis[J]. Cureus,2021,13(1):e12735.
[9] Gao Q,Wei A,Chen F,et al. Enhancing PPARγ by HDAC inhibition reduces foam cell formation and atherosclerosis in ApoE deficient mice[J]. Pharmacol Res,2020,160:105059.
[10] Manea S,Vlad M,Fenyo I,et al. Pharmacological inhibition of histone deacetylase reduces NADPH oxidase expression,oxidative stress and the progression of atherosclerotic lesions in hypercholesterolemic apolipoprotein E-deficient mice; potential implications for human atherosclerosis[J]. Redox Biol,2020,28:101338.
[11] Chen J,Luo Y,Wang S,et al. Roles and mechanisms of SUMOylation on key proteins in myocardial ischemia/reperfusion injury[J].J Mol Cell Cardiol,2019,134:154-164.
[12] Lin CF, Hsu KC, HuangFu WC,et al. Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury[J]. BMC Pharmacol Toxicol,2020,21(1):21.
[13] Tian S,Lei I,Gao W,et al. HDAC inhibitor valproic acid protects heart function through Foxm1 pathway after acute myocardial infarction[J]. EBioMedicine,2019,39:83-94.
[14] Shang L,Pin L,Zhu S,et al. Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3β signaling pathway[J]. Chem Biol Interact,2019,307:21-28.
[15] Zhang L,Deng M,Lu A,et al. Sodium butyrate attenuates angiotensin Ⅱ-induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6-dependent mechanism[J]. J Cell Mol Med,2019,23(12):8139-8150.
[16] Zhao T,Kee H,Bai L,et al. Selective HDAC8 inhibition attenuates isoproterenol-induced cardiac hypertrophy and fibrosis via p38 MAPK pathway[J]. Front Pharmacol,2021,12:677757.
[17] Liao PP, Liu LH, Wang B,et al. Correlation between histone deacetylase 9 and regulatory T cell in patients with chronic heart failure[J]. Curr Med Sci,2018,38(2):199-203.
[18] Nagata S,Marunouchi T,Tanonaka KJB,et al. Histone deacetylase inhibitor SAHA treatment prevents the development of heart failure after myocardial infarction via an induction of heat-shock proteins in rats[J]. Biol Pharm Bull,2019,42(3):453-461.
[19] Nural-Guvener H, Zakharova L, Feehery L,et al. Anti-fibrotic effects of class I HDAC inhibitor,mocetinostat is associated with IL-6/stat3 signaling in ischemic heart failure[J].Int J Mol Sci,2015,16(5):11482-11499.
[20] Travers J,Wennersten S,Pe?a B,et al. HDAC inhibition reverses preexisting diastolic dysfunction and blocks covert extracellular matrix remodeling[J].Circulation,2021,143(19):1874-1890.
[21] Zhang D,Hu X,Li J,et al. Converse role of class Ⅰ and class Ⅱa HDACs in the progression of atrial fibrillation[J]. J Mol Cell Cardiol,2018,125:39-49.
[22] Rahm AK,Wieder T,Gramlich D,et al. HDAC2-dependent remodeling of K2.2 (KCNN2) and K2.3 (KCNN3) K channels in atrial fibrillation with concomitant heart failure[J].Life Sci, 2021,266:118892.
[23] van Marion D,Lanters E,Wiersma M,et al. Diagnosis and therapy of atrial fibrillation:the past,the present and the future[J]. J Atr Fibrillation,2015,8(2):1216.
[24] Zhang D,Wu C,Qi X,et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation[J]. Circulation,2014,129(3):346-358.